Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. (24th January 2018)

• Record Type: Journal Article
• Authors: Dong, Minhui; Wu, Jingwen; Yu, Xueping; Li, Jing; Yang, Sisi; Qi, Xun; Mao, Richeng; Zhang, Yongmei; Yu, Jie; Zhu, Haoxiang; Yang, Feifei; Qin, Yanli; Zhang, Jiming
• Is Part Of: Liver international. Volume 38:Number 9(2018)
• Page Start: 1562
• Page End: 1570
• Publication Date: 2018-01-24
• Subjects: hepatitis B -- liver fibrosis -- noninvasive models; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.13688
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background & Aims: To avoid liver biopsy, many noninvasive models comprised of serum markers for liver fibrosis assessment have been developed. Given that most of them were developed in hepatitis C cohorts and few of them have been validated in Chinese hepatitis B patients, we aim to conduct this validation and compare their diagnostic accuracies in such a population. Methods: A total of 937 HBV‐infected patients who underwent liver biopsy were included in this single‐centre retrospective study. The diagnostic accuracies of the 17 noninvasive models were assessed by areas under the receiver‐operating characteristic curves (AUROCs), using histologically evaluated fibrotic stages of the biopsy specimens as standards. To compare efficiencies of the models, a grading system based on AUROC levels was developed. Results: For discriminating significant fibrosis in all patients, the best three noninvasive models were King's score (AUROC = 0.756), Virahep‐C model (AUROC = 0.756) and GPR (AUROC = 0.744); and for diagnosing cirrhosis, Lok index (AUROC = 0.832), FI (AUROC = 0.820) and FIB‐4 (AUROC = 0.818) got the first three places. AUROCs in HBeAg‐positive group were generally higher than those in HBeAg‐negative group. In addition, based on the grading system, Virahep‐C and GPR outstood others in evaluating liver fibrosis in all patients. Conclusions: In Chinese HBV‐infected patients, Virahep‐C models and GPR had high accuracies in diagnosing liver fibrosis and cirrhosis, while the most discussed models like APRI and FIB‐4 did not outstand. Assessment should take into account the HBeAg sero‐status, since these noninvasive models were more appropriate for HBeAg‐positive patients than HBeAg‐negative ones.